Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAEK-VAC-HerBy |
Synonyms | |
Therapy Description |
TAEK-VAC-HerBy is a cancer vaccine targeted against Erbb2 (Her2) receptor on tumor cells, and may lead to inhibition of cell proliferation, induction of a T-cell immune response, and tumor cell killing (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAEK-VAC-HerBy | TAEK-VAC-HerBy Vaccine | HER2 (ERBB2) Vaccine 14 | TAEK-VAC-HerBy is a cancer vaccine targeted against Erbb2 (Her2) receptor on tumor cells, and may lead to inhibition of cell proliferation, induction of a T-cell immune response, and tumor cell killing (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer | Active, not recruiting | USA | 0 |